Shenzhen Hepalink Pharmaceutical Co Ltd (002399) - Total Assets

Latest as of December 2025: CN¥16.63 Billion CNY ≈ $2.43 Billion USD

Based on the latest financial reports, Shenzhen Hepalink Pharmaceutical Co Ltd (002399) holds total assets worth CN¥16.63 Billion CNY (≈ $2.43 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 002399 total equity for net asset value and shareholders' equity analysis.

Shenzhen Hepalink Pharmaceutical Co Ltd - Total Assets Trend (2006–2025)

This chart illustrates how Shenzhen Hepalink Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.

Shenzhen Hepalink Pharmaceutical Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Shenzhen Hepalink Pharmaceutical Co Ltd's total assets of CN¥16.63 Billion consist of 55.0% current assets and 45.0% non-current assets.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	8.1%
Accounts Receivable	CN¥1.37 Billion	8.2%
Inventory	CN¥4.45 Billion	26.7%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥327.12 Million	2.0%
Goodwill	CN¥2.30 Billion	13.9%

Asset Composition Trend (2006–2025)

This chart illustrates how Shenzhen Hepalink Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Shenzhen Hepalink Pharmaceutical Co Ltd worth.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Shenzhen Hepalink Pharmaceutical Co Ltd's current assets represent 55.0% of total assets in 2025, a decrease from 88.9% in 2006.
Cash Position: Cash and equivalents constituted 8.1% of total assets in 2025, down from 43.6% in 2006.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 0.0% in 2006.
Asset Diversification: The largest asset category is inventory at 26.7% of total assets.

Shenzhen Hepalink Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Shenzhen Hepalink Pharmaceutical Co Ltd based on total assets are shown below.

Company	Country	Total Assets
Changchun High & New Technology Industries Group Inc SHE:000661	China	CN¥31.46 Billion
Yuhan Corp. KO:000100	Korea	₩3.05 Trillion
Tasly Pharmaceutical Group Co Ltd SHG:600535	China	CN¥15.34 Billion
Zhejiang Hisun Pharmaceutical Co Ltd SHG:600267	China	CN¥15.32 Billion
Zhejiang Jiuzhou Pharm Co Ltd SHG:603456	China	CN¥10.96 Billion
Shanghai Yizhong Pharmaceutical Co Ltd SHG:688091	China	CN¥1.54 Billion
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	China	CN¥6.74 Billion
Cronos Group Inc TO:CRON	Canada	CA$1.18 Billion

Shenzhen Hepalink Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	2.31	2.60	2.78
Quick Ratio	1.19	1.14	1.85
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥5.20 Billion	CN¥5.92 Billion	CN¥6.56 Billion

Shenzhen Hepalink Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Shenzhen Hepalink Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	1.37
Latest Market Cap to Assets Ratio	0.12
Asset Growth Rate (YoY)	-4.1%
Total Assets	CN¥16.63 Billion
Market Capitalization	$1.98 Billion USD

Valuation Analysis

Below Book Valuation: The market values Shenzhen Hepalink Pharmaceutical Co Ltd's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Shenzhen Hepalink Pharmaceutical Co Ltd's assets decreased by 4.1% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)

The table below shows the annual total assets of Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2025.

Year	Total Assets	Change
2025-12-31	CN¥16.63 Billion ≈ $2.43 Billion	-4.10%
2024-12-31	CN¥17.34 Billion ≈ $2.54 Billion	-9.69%
2023-12-31	CN¥19.20 Billion ≈ $2.81 Billion	-7.74%
2022-12-31	CN¥20.81 Billion ≈ $3.05 Billion	+8.93%
2021-12-31	CN¥19.11 Billion ≈ $2.80 Billion	+0.43%
2020-12-31	CN¥19.03 Billion ≈ $2.78 Billion	+24.82%
2019-12-31	CN¥15.24 Billion ≈ $2.23 Billion	+11.62%
2018-12-31	CN¥13.66 Billion ≈ $2.00 Billion	+3.53%
2017-12-31	CN¥13.19 Billion ≈ $1.93 Billion	+2.14%
2016-12-31	CN¥12.91 Billion ≈ $1.89 Billion	+6.12%
2015-12-31	CN¥12.17 Billion ≈ $1.78 Billion	+22.54%
2014-12-31	CN¥9.93 Billion ≈ $1.45 Billion	+20.06%
2013-12-31	CN¥8.27 Billion ≈ $1.21 Billion	+0.14%
2012-12-31	CN¥8.26 Billion ≈ $1.21 Billion	+3.58%
2011-12-31	CN¥7.97 Billion ≈ $1.17 Billion	-1.88%
2010-12-31	CN¥8.13 Billion ≈ $1.19 Billion	+490.36%
2009-12-31	CN¥1.38 Billion ≈ $201.44 Million	+137.79%
2008-12-31	CN¥578.92 Million ≈ $84.71 Million	+124.63%
2007-12-31	CN¥257.73 Million ≈ $37.71 Million	-26.16%
2006-12-31	CN¥349.01 Million ≈ $51.07 Million	--

About Shenzhen Hepalink Pharmaceutical Co Ltd

SHE:002399 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.98 Billion

CN¥13.56 Billion CNY

Market Cap Rank

#6301 Global

#1396 in China

Share Price

CN¥10.87

Change (1 day)

+0.93%

52-Week Range

CN¥10.33 - CN¥13.88

All Time High

CN¥28.69